Medicare Patient Access to Cancer Treatment Act

Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484

Client expense: Not reported · Firm income: Not reported

Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency,real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484

Client expense: Not reported · Firm income: Not reported

Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA Reauthorization; Healthcare innovation, ARPA-H, oncology research; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting; Pharmaceutical Manufacturing and Supply Chain Shortage; Alleviating Drug Shortages; Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; HR 2484 Seniors Access to Critical Medications Act.

Client expense: $1,220,000 · Firm income: Not reported

HR 4758 / S 2372, the Accelerating Kids Access to Care Act; HR 5526 / S 3458, the Seniors' Access to Critical Medications Act; HR 8702 / S 4532, Improving Seniors Timely Access to Care Act; HR 1613, the Drug Price Transparency in Medicaid Act; HR 4473, the Medicare Patient Access to Cancer Treatment Act; HR 5378, The Lower Costs, More Transparency Act; HR 7512, the Real-Time Benefit Tool Implementation Act; S 2186, the Improving Access to Transfusion Care for Hospice Patients Act; S 1869, the Site-based Invoicing and Transparency Enhancement (SITE) Act; S 4349, the Electronic Prior Authorization for Prescription Drugs Act Implementation of the Inflation Reduction Act, specifically provisions relating to the Medicare Part D annual and monthly maximum out-of-pocket caps; Proposals to add work requirements to Medicaid programs; Medicaid policies related to the end of certain federal Medicaid maintenance-of-effort requirements; Proposals to promote parity in certain Medicare reimbursement across hospital outpatient and provider office settings;

Client expense: $180,000 · Firm income: Not reported

Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response; PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R. 7623: Telehealth Modernization Act of 2024; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.

Client expense: $560,000 · Firm income: Not reported

Medicare/Medicaid - H.R. 5378, the Lower Costs, More Transparency Act; H.R. 4473, the Medicare Patient Access to Cancer Treatment Act; S. 1869, the Site-based Invoicing and Transparency Enhancement Act

Client expense: $119,898 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).

Client expense: $56,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).

Client expense: $119,942 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).

Client expense: $46,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

HR 4758 / S 2372, the Accelerating Kids Access to Care Act; HR 5526 / S 3458, the Seniors' Access to Critical Medications Act; HR 8702 / S 4532, Improving Seniors Timely Access to Care Act; HR 1613, the Drug Price Transparency in Medicaid Act; HR 4473, the Medicare Patient Access to Cancer Treatment Act; HR 5378, The Lower Costs, More Transparency Act; HR 7512, the Real-Time Benefit Tool Implementation Act; S 2186, the Improving Access to Transfusion Care for Hospice Patients Act; S 1869, the Site-based Invoicing and Transparency Enhancement (SITE) Act; S 4349, the Electronic Prior Authorization for Prescription Drugs Act Implementation of the Inflation Reduction Act, specifically provisions relating to the Medicare Part D annual and monthly maximum out-of-pocket caps; Proposals to add work requirements to Medicaid programs; Medicaid policies related to the end of certain federal Medicaid maintenance-of-effort requirements; Proposals to promote parity in certain Medicare reimbursement across hospital outpatient and provider office settings;

Client expense: $160,000 · Firm income: Not reported

Medicare/Medicaid - H.R.5526, the Resident Physician Shortage Act; H.R. 3441 the Substance Use Disorder Workforce Act; H.R. 5376; H.R. 5378, the Lower Costs, More Transparency Act; H.R. 4473, the Medicare Patient Access to Cancer Treatment Act; S. 1869, the Site-based Invoicing and Transparency Enhancement Act

Client expense: $115,879 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act

Client expense: $640,000 · Firm income: Not reported

HR 4758 / S 2372, the Accelerating Kids Access to Care Act; HR 5526 / S 3458, the Seniors' Access to Critical Medications Act; HR 1613, the Drug Price Transparency in Medicaid Act; HR 4473, the Medicare Patient Access to Cancer Treatment Act; HR 5378, The Lower Costs, More Transparency Act; HR 7512, the Real-Time Benefit Tool Implementation Act; S 2186, the Improving Access to Transfusion Care for Hospice Patients Act; S. 1869, the Site-based Invoicing and Transparency Enhancement (SITE) Act Implementation of the Inflation Reduction Act, specifically provisions relating to the Medicare Part D annual and monthly maximum out-of-pocket caps; Proposals to add work requirements to Medicaid programs; Medicaid policies related to the end of certain federal Medicaid maintenance-of-effort requirements; Proposals to promote parity in certain Medicare reimbursement across hospital outpatient and provider office settings;

Client expense: $570,000 · Firm income: Not reported

Medicare/Medicaid - H.R.5526, the Resident Physician Shortage Act; H.R. 3441 the Substance Use Disorder Workforce Act; H.R. 5376; H.R. 5378, the Lower Costs, More Transparency Act; H.R. 4473, the Medicare Patient Access to Cancer Treatment Act

Client expense: $115,675 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822), Accelerating Kids Access to Care Act(HR 3089, S 1544) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).

Client expense: $56,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act

Client expense: $650,000 · Firm income: Not reported

HR 4758 / S 2372, the Accelerating Kids Access to Care Act; HR 5378, The Lower Costs, More Transparency Act; HR 7512, the Real-Time Benefit Tool Implementation Act; HR 5526 / S 3458, the Seniors' Access to Critical Medications Act; HR 4473, the Medicare Patient Access to Cancer Treatment Act; S 2186, the Improving Access to Transfusion Care for Hospice Patients Act; S. 1869, the Site-based Invoicing and Transparency Enhancement (SITE) Act HR 1613, the Drug Price Transparency in Medicaid Act; Implementation of the Inflation Reduction Act, specifically provisions relating to the Medicare Part D annual and monthly maximum out-of-pocket caps; Proposals to add work requirements to Medicaid programs; Medicaid policies related to the end of certain federal Medicaid maintenance-of-effort requirements; Proposals to promote parity in certain Medicare reimbursement across hospital outpatient and provider office settings;

Client expense: $100,000 · Firm income: Not reported

Medicare/Medicaid - H.R.5526, the Resident Physician Shortage Act; H.R. 3441 the Substance Use Disorder Workforce Act; H.R. 5376; H.R. 5378, the Lower Costs, More Transparency Act; H.R. 4473, the Medicare Patient Access to Cancer Treatment Act

Client expense: $116,696 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare/Medicaid - H.R.5526, the Resident Physician Shortage Act; H.R. 3441 the Substance Use Disorder Workforce Act; H.R. 5376; H.R. 5378, the Lower Costs, More Transparency Act; H.R. 4473, the Medicare Patient Access to Cancer Treatment Act

Client expense: $116,647 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).

Client expense: $169,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act

Client expense: $1,580,000 · Firm income: Not reported

Medicare/Medicaid - H.R.5526, the Resident Physician Shortage Act; H.R. 3441 the Substance Use Disorder Workforce Act; H.R. 5376, the Consolidated Appropriations Act, 2021; H.R. 5378, the Lower Costs, More Transparency Act; H.R. 4473, the Medicare Patient Access to Cancer Treatment Act

Client expense: $117,130 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Congressional outreach and monitoring regarding the following: -Healthcare and hospital workforce appropriations, generally; -FEMA funding, generally; -H.R. 4368 / S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 (including Rural Healthcare Funding); -H.R. 5894 / S. 2624, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; -340B Drug Discount Program & HRSA/CMS policies; -CMS Wage Index; -Medicare reimbursement rates, generally; -Medicare Site Neutral Payments; -Medicaid Disproportionate Share Hospital (DSH) payments; -Graduate Medical Education; -H.R. 2377 / S. 1000, Saving Access to Laboratory Services Act; -H.R. 2584 / S. 2768, Safety From Violence for Healthcare Employees (SAVE) Act; -H.R. 4473, Medicare Patient Access to Cancer Treatment (MPACT) Act; -H.R. 5378, Lower Costs, More Transparency Act; -S. 1869, Site-based Invoicing and Transparency Enhancement (SITE) Act.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Congressional outreach and monitoring regarding the following: -Healthcare and hospital workforce appropriations, generally; -FEMA funding, generally; -H.R. 4368 / S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024 (including Rural Healthcare Funding); -H.R. 5894 / S. 2624, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes; -340B Drug Discount Program & HRSA/CMS policies; -CMS Wage Index; -Medicare reimbursement rates, generally; -Medicare Site Neutral Payments; -Medicaid Disproportionate Share Hospital (DSH) payments; -Graduate Medical Education; -H.R. 2377 / S. 1000, Saving Access to Laboratory Services Act; -H.R. 2584 / S. 2768, Safety From Violence for Healthcare Employees (SAVE) Act; -H.R. 4473, Medicare Patient Access to Cancer Treatment (MPACT) Act; -H.R. 5378, Lower Costs, More Transparency Act; -S. 1869, Site-based Invoicing and Transparency Enhancement (SITE) Act.

Client expense: Not reported · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1770, S.2477: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; Alleviating drug shortages; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act

Client expense: $720,000 · Firm income: Not reported

Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).

Client expense: $77,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Congressional outreach and monitoring regarding the following: -Healthcare and hospital workforce appropriations, generally; -FEMA funding, generally; -Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, FY2024 (including Rural Healthcare Funding); -Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations, FY2024; -340B Drug Discount Program & HRSA/CMS policies; -CMS Wage Index; -Medicare reimbursement rates, generally; -Medicare Site Neutral Payments; -Medicaid Disproportionate Share Hospital (DSH) payments; -Graduate Medical Education; -H.R. 2377 / S. 1000, Saving Access to Laboratory Services Act; -H.R. 2584, Safety From Violence for Healthcare Employees (SAVE) Act; -H.R. 4473, Medicare Patient Access to Cancer Treatment (MPACT) Act; -H.R. 5378, Lower Costs, More Transparency Act; -S. 1869, Site-based Invoicing and Transparency Enhancement (SITE) Act.

Client expense: $10,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Congressional outreach and monitoring regarding the following: -Healthcare and hospital workforce appropriations, generally; -FEMA funding, generally; -Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations, FY2024 (including Rural Healthcare Funding); -Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations, FY2024; -340B Drug Discount Program & HRSA/CMS policies; -CMS Wage Index; -Medicare reimbursement rates, generally; -Medicare Site Neutral Payments; -Medicaid Disproportionate Share Hospital (DSH) payments; -Graduate Medical Education; -H.R. 2377 / S. 1000, Saving Access to Laboratory Services Act; -H.R. 2584, Safety From Violence for Healthcare Employees (SAVE) Act; -H.R. 4473, Medicare Patient Access to Cancer Treatment (MPACT) Act; -H.R. 5378, Lower Costs, More Transparency Act; -S. 1869, Site-based Invoicing and Transparency Enhancement (SITE) Act.

Client expense: $10,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; H.R. 3008 Drug Shortage Prevention Act; H.R. 3793 Ensuring Access to Lifesaving Drugs Act; S. 2364 Mapping Americas Pharmaceutical Supply (MAPS) Act; S.2510 RAPID Reserve Act; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 5378, Lower Cost, More Cures Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act; H.R. 3674, Providing Relief and Stability for Medicare Patients Act; H.R. 5391, S. 2764 Protecting Patient Access to Cancer and Complex Therapies Act.

Client expense: $530,000 · Firm income: Not reported

Affordability; Affordable Care Act; Mental health/Youth Mental Health; Maternal Health; Health Equity; Site Neutrality/site neutral payment reform; Fair Hospital Billing; Transparency in coverage; Surprise Billing; Government shutdown; Rural healthcare access; HIPAA modernization; Artificial intelligence (AI); Preventative services S.1869 - SITE Act To amend title XVIII of the Social Security Act and title XXVII of the Public Health Service Act to ensure fair billing practice for items and services furnished by off-campus hospital locations, to amend such title XVIII to provide for payments for graduate nursing education costs, and for other purposes. H.R. 3561, The Patient Act of 2023To promote hospital and insurer price transparency, and for other purposes. H.R.3417 - FAIR Act to ensure fair billing practices for items and services furnished by off-campus outpatient departments of a provider. H.R. 5378 Lower Costs, More Transparency Act to promote price transparency in the health care sector, and for other purposes. H.R.4822 Health Care Price Transparency Act of 2023To improve price transparency with respect to certain health care services, and for other purpose. H.R.4509 - Transparency in Billing Act to amend the Employee Retirement Income Security Act of 1974 to require group health plans and health insurance issuers offering group health insurance coverage to only pay claims submitted by hospitals that have in place policies and procedures to ensure accurate billing practices, and for other purposes. H.R.4508 - Hidden Fee Disclosure Act to amend the Employee Retirement Income Security Act of 1974 to clarify and strengthen the application of certain employer-sponsored health plan disclosure requirements H.R.4507 - Transparency in Coverage Act of 2023 to amend the Employee Retirement Income Security Act of 1974 to promote transparency in health coverage and reform pharmacy benefit management services with respect to group health plans, and for other purposes. H.R.4527 - Health DATA Act to amend the Employee Retirement Income Security Act of 1974 to ensure plan fiduciaries may access de-identified information relating to health claims, and for other purposes. H.R.5647 - Childhood Cancer Clinical Trials Act to amend title XXVII of the Public Health Service Act to require out-of-network coverage for qualified individuals diagnosed with a rare pediatric disease participating in approved clinical trials, and for other purposes. H.R.5687 - HSA Modernization Act of 2023To amend the Internal Revenue Code of 1986 to modernize health savings accounts. H.R.4473 Medicare Patient Access to Treatment Act.

Issues related to health care access and reimbursement through the Medicare and Medicaid programs including site neutrality and prior authorization policies in the Medicare program, specifically, The PATIENT Act of 2023 (H.R. 3561),the Healthcare Price Transparency Act (H.R. 4822) and The Medicare Patient Access to Cancer Treatment (MPACT) Act (H.R. 4473).

Client expense: $75,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 4189: CONNECT Act - provisions related to permanently extending pandemic era telehealth rules. S. 2016: CONNECT Act - provisions related to permanently extending pandemic era telehealth rules. H.R. 1843: Telehealth Expansion Act of 2023 - provisions related to allowing HSA accounts towards telehealth. S. 1001: Telehealth Expansion Act of 2023 - provisions related to allowing HSA accounts towards telehealth. H.R. 4942: Conrad State 30 and Physician Access Reauthorization Act - provisions related to highly-skilled visa renewal. S. 665: Conrad State 30 and Physician Access Reauthorization Act - provisions related to highly-skilled visa renewal. H.R. 5378: Lower Cost Increase Transparency Act - provisions related to expanding access to health care. H.R. 5687: the HSA Modernization Act of 2023 - provisions related to expanding access to HSAs for veterans. H.R. 5688: the Bipartisan HSA Improvement Act of 2023 - provisions related to innovating direct primary care and HSA compatbility. H.R. 5608: Affordable Care and Comprehensive Economic Support through Savings Act - provisions related to expanding HSA access. H.R. 4509: Transparency in Billing Act - provisions realted to health care billing and pricing transparency. H.R. 4507: Transparency in Coverage Act of 2023 - provisions related to health care coverage transparency. S. 1869: SITE Act - provisions related to medicare payouts. H.R. 3129: Health Care Fairness for All Act - provisions related to expanding access to health savings accounts. H.R. 3029: Primary Care Enhancement Act of 2023 - provisions related to expanding access to direct primary care. S. 628: Primary Care Enhancement Act of 2023 - provisions related to expanding access to direct primary care. H.R. 2959: Health Savings Act of 2023 - provisions related to expanding access to health savings accounts. S. 1158: Health Savings Act of 2023 - provisions related to expanding access to health savings accounts. S. 470: Patient Access to Higher Quality Health Care Act of 2023 - provisions related to expanding physician-owned hospitals. H.R. 977: Patient Access to Higher Quality Health Care Act of 2023 - provisions related to expanding physician-owned hospitals. H.R. 3799: CHOICE Arrangement Act - provisions related to expanding health care option in workplace health plans. H.R. 3561: PATIENT Act of 2023 - provisions related to increasing transparency in health care pricing. H.R. 4473: Medicare Patient Access to Cancer Treatment Act - provisions related to expanding health care treatment. H.R. 4091: To amend the SUPPORT for Patients and Communities Act to expand required reports on T-MSIS substance use disorder data to include mental health condition data. - provisions related to mental health care. S. 2305: Biosimilar Act - provisions related to increasing access to generic drugs. S. 2505: Biosimilar Red Tap Elimination Act - provisions related to increasing access to generic drugs. H.R. 2840: Bipartisan Primary Care and Health Workforce Act - provisions related to primary care access. H.R. 2769: Stop Penalizing Working Seniors Act - provisions related to expansion of HSAs. H.R. 1769: Healthcare Freedom Act of 2023 - provisions related to expansion of HSAs. Issues relating to the unintroduced All Hazards Preparedness Act. Issues relating to health care billing and pricing transparency. Issues relating to the unintroduced Personalized Care Act.

- Support for HR 2474 Re: Strengthening Medicare for Patients and Providers Act. This bipartisan legislation advances the ongoing need to provide financial stability to physician practices in order to preserve access to care for Medicare beneficiaries. - Support for HR 4473 or The Medicare Patient Access to Cancer Treatment Act of 2023. This bill is part of a multi-pronged response - one that folds in Medicare physician payment reform, site neutrality, and other changes - to disincentivize consolidation, preserve independent practice viability, and ensure patients have options when seeking care.

Client expense: $10,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare/Medicaid - H.R.5526, the Resident Physician Shortage Act; H.R. 3441 the Substance Use Disorder Workforce Act; H.R. 5376, the Consolidated Appropriations Act, 2021; H.R. 5378, the Lower Costs, More Transparency Act; H.R. 4473, the Medicare Patient Access to Cancer Treatment Act

Client expense: $115,615 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Medicare reimbursements for cancer services. Any legislation having to do with Medicare payments for dedicated cancer centers and hospitals; Medicare Advantage and preauthorization. Cuts to services related to cancer diagnosis and treatment. Hospital site of service payment policy changes. Issues related to increased access to cancer detection. Issues related to "White Bagging" of pharmaceutical products. H.R. 4473 Medicare Patient Access to Cancer Treatment; H.R. 3561 The PATIENT Act of 2023 H.R. 4822 Healthcare Price Transparency Act; S.1869 Site-based Invoicing and Transparency Enhancement

Client expense: $75,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1770: Equitable Community Access to Pharmacist Services Act; Clinical trial diversity, health equity; Emergency preparedness and response. PAHPA reauthorization H.R. 4420 and 4421, S.2333; Healthcare innovation, ARPA-H, oncology research; H.R. 1835: Saving Access to Laboratory Services Act; Community Health Center Reauthorization; Benefit cost and transparency, real time benefit tools and patient APIs - S. 1339; Controlled Substance Reporting - H.R. 501; Pharmaceutical Manufacturing and Supply Chain Shortage - H.R. 3793; H.R.4011 Timely Access to Cancer Treatment Act; H.R.2630, S.652 The Safe Step Act; H.R. 2474, Strengthening Medicare for Patients and Providers Act; H.R. 3561, PATIENT Act; H.R. 4473, Medicare Patient Access to Cancer Treatment Act.

Client expense: $510,000 · Firm income: Not reported